Please login to the form below

Not currently logged in
Email:
Password:

personalised treatments

This page shows the latest personalised treatments news and features for those working in and with pharma, biotech and healthcare.

Europe's public-private alliance targets pain management

Europe's public-private alliance targets pain management

be used to develop more personalised treatments.

Latest news

  • Disruptive technologies set to stabilise soaring drug prices Disruptive technologies set to stabilise soaring drug prices

    Artificial intelligence (AI), big data and blockchain are set to impact the industry, not only by helping to add value in terms of personalised treatments, but to also counteract the unsustainability

  • Roche to buy cancer data firm Flatiron for $1.9bn Roche to buy cancer data firm Flatiron for $1.9bn

    Roche Pharma chief executive Daniel O’Day “is a key ingredient to accelerate the development of, and access to, new cancer treatments”. ... The GNS collaboration is “aimed at generating unique insights from a growing volume of genomic and

  • The future of biotech The future of biotech

    Patients in those markets will be encouraged to select treatments that offer value. ... There are several reasons. The combination of the Human Genome Project and the commercial application of diagnostics have created opportunities to develop more

  • Novo Nordisk will work with IBM on diabetes care Novo Nordisk will work with IBM on diabetes care

    based on "insights from real-time, real-world evidence of … diabetes treatments and devices". ... IBM Watson Health's earlier collaboration with Medtronic is also in the area of diabetes and is aimed at delivering personalised treatments for diabetics

  • 2015: A year of promise and connectivity 2015: A year of promise and connectivity

    step closer to true personalised medicines and treatments. ... forthcoming. Tie this into the genetic information that is becoming available from companies such as 23andMe, and we are moving ever closer to a personalised healthcare environment.

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Reactivating drug research programmes Reactivating drug research programmes

    The actual number of drug trials that are abandoned each year before treatments reach the marketplace is unknown, at least at a global level. ... However, as drugs like Herceptin have shown, as long as there is a high degree of efficacy in a small group

  • Winning the war against cancer Winning the war against cancer

    From the variation among cancer registries to the recording of how well different treatments work, information is key. ... The next five years are expected to see a wave of new oncology medicines that will address significant unmet medical needs, with

  • Another lost decade for research? Another lost decade for research?

    We are emerging from a decade of intensive research into rare disease treatments. ... Such technologies, which allow doctors to diagnose bacterial from viral infections or distinguish between different bacteria, could lead to personalised treatments and

  • What can pharma learn from Olympic sports coverage? What can pharma learn from Olympic sports coverage?

    It has got marketing channels into the medical community, and it has got the research base to help translate emerging genomic discoveries into clinical information and personalised treatments in development. ... If personalised healthcare is going to

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Doctors and patients want more tailored solutions and a more personalised approach: “ Drugs are not being sold to a broad patient group, but need to take into account individual patient needs. ... Out-of-pocket contributions are likely to increase, as

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Horizon adds AZ’s Galbraith to board Horizon adds AZ’s Galbraith to board

    Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments.

  • Horizon appoints board chair Horizon appoints board chair

    These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics